{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:30:21Z","timestamp":1794475821205,"version":"4.9.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cancer Policy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jcpo.2026.100760","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T23:43:20Z","timestamp":1780443800000},"page":"100760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cost-effectiveness and budget impact analysis of pembrolizumab as an adjuvant treatment of resected stage III melanoma from an Australian healthcare system perspective"],"prefix":"10.1016","volume":"49","author":[{"given":"Rashidul Alam","family":"Mahumud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcpo.2026.100760_bib1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cpt.2024.08.002","article-title":"Overview of skin cancer types and prevalence rates across continents","volume":"3","author":"Roky","year":"2025","journal-title":"Cancer Pathog. Ther."},{"key":"10.1016\/j.jcpo.2026.100760_bib2","unstructured":"Cancer Australia. Melanoma of the skin statistics. Melanoma Ski. \u3008https:\/\/www.canceraustralia.gov.au\/cancer-types\/melanoma-skin\/melanoma-skin-statistics\u3009 (accessed March 11, 2026)."},{"key":"10.1016\/j.jcpo.2026.100760_bib3","unstructured":"Australian Institute of Health and Welfare. Cancer data in Australia. 2024. \u3008https:\/\/www.aihw.gov.au\/reports\/cancer\/cancer-data-in-australia\u3009 (accessed Sept 20, 2025)."},{"key":"10.1016\/j.jcpo.2026.100760_bib4","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1056\/NEJMoa2404139","article-title":"Final results for adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"391","author":"Long","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcpo.2026.100760_bib5","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcpo.2026.100760_bib6","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s11912-022-01288-y","article-title":"Treatment approaches for melanomas that relapse after adjuvant or neoadjuvant therapy","volume":"24","author":"Ng","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.jcpo.2026.100760_bib7","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jid.2016.01.035","article-title":"The Growing Burden of Invasive Melanoma: Projections of Incidence Rates and Numbers of New Cases in Six Susceptible Populations through 2031","volume":"136","author":"Whiteman","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jcpo.2026.100760_bib8","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcpo.2026.100760_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/EVIDoa2200214","article-title":"Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma","volume":"1","author":"Eggermont","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.jcpo.2026.100760_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114327","article-title":"Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 \/ KEYNOTE-054 trial","volume":"211","author":"Eggermont","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jcpo.2026.100760_bib11","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1080\/13696998.2019.1609485","article-title":"Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States","volume":"22","author":"Bensimon","year":"2019","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.jcpo.2026.100760_bib12","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1007\/s12325-023-02484-3","article-title":"Cost-effectiveness of pembrolizumab as an adjuvant treatment in Colombia for melanoma patients with lymph node involvement after complete resection","volume":"40","author":"Lopez-Vinueza","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jcpo.2026.100760_bib13","series-title":"Methods for the economic evaluation of health care programmes, Fourth","author":"Drummond","year":"2015"},{"key":"10.1016\/j.jcpo.2026.100760_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114327","article-title":"Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 \/ KEYNOTE-054 trial","volume":"211","author":"Eggermont","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jcpo.2026.100760_bib15","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jval.2018.01.017","article-title":"Comparing the ICERs in Medicine Reimbursement Submissions to NICE and PBAC \u2014 Does the Presence of an Explicit Threshold Affect the ICER Proposed","volume":"21","author":"Wang","year":"2018","journal-title":"Value Heal."},{"key":"10.1016\/j.jcpo.2026.100760_bib16","unstructured":"Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the PBAC: Section 3A, Cost-effectiveness analysis. Australian Government Department of Health and Aged Care., 2016 \u3008https:\/\/pbac.pbs.gov.au\/section-3a\/3a-1-overview-and-rationale-of-economic-evaluation.html\u3009."},{"key":"10.1016\/j.jcpo.2026.100760_bib17","unstructured":"Cancer Australia. Melanoma of the skin statistics. 2025. \u3008https:\/\/www.canceraustralia.gov.au\/cancer-types\/melanoma-skin\/melanoma-skin-statistics\u3009 (accessed May 26, 2026)."},{"key":"10.1016\/j.jcpo.2026.100760_bib18","unstructured":"Cancer Council Victoria. Melanoma cancer statistics and trends. Vic. Cancer Regist. 2025."},{"key":"10.1016\/j.jcpo.2026.100760_bib19","unstructured":"Australian Government Department of Health. Government strengthens support for melanoma patients with breakthrough treatment expanded on PBS. Australian Government Department of Health media release. Canberra: Department of Health, 2020."},{"key":"10.1016\/j.jcpo.2026.100760_bib20","doi-asserted-by":"crossref","first-page":"290","DOI":"10.6004\/jnccn.2024.0036","article-title":"NCCN Guidelines\u00ae Insights: Melanoma: Cutaneous, Version 2.2024","volume":"22","author":"Swetter","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.jcpo.2026.100760_bib21","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s40261-020-00922-6","article-title":"An economic evaluation of pembrolizumab versus other adjuvant treatment strategies for resected high-risk stage III Melanoma in the USA","volume":"40","author":"Bensimon","year":"2020","journal-title":"Clin. Drug. Investig."},{"key":"10.1016\/j.jcpo.2026.100760_bib22","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40487-021-00142-8","article-title":"Cost-effectiveness of pembrolizumab for the adjuvant treatment of melanoma patients with lymph node involvement who have undergone complete resection in Argentina","volume":"9","author":"Wurcel","year":"2021","journal-title":"Oncol. Ther."},{"key":"10.1016\/j.jcpo.2026.100760_bib23","unstructured":"Australian Bureau of Statistics Life tables, age and sex by Australia-2021-2023. 2024 \u3008https:\/\/www.abs.gov.au\/statistics\/people\/population\/life-expectancy\/latest-release#data-downloads\u3009."},{"key":"10.1016\/j.jcpo.2026.100760_bib24","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcpo.2026.100760_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-017-3673-y","article-title":"Societal preferences for adjuvant melanoma health states: UK and Australia","volume":"17","author":"Middleton","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jcpo.2026.100760_bib26","unstructured":"Independent Health and Aged Care Pricing Authority (IHACPA). National Efficient Price Determination 2025\u201326. Canberra: IHACPA, 2025 \u3008https:\/\/www.ihacpa.gov.au\/resources\/national-efficient-price-determination-2025-26\u3009."},{"key":"10.1016\/j.jcpo.2026.100760_bib27","unstructured":"AIHW. Palliative care services in Australia. Aust. Inst. Heal. Welf. 2025. \u3008https:\/\/www.aihw.gov.au\/reports\/palliative-care-services\/palliative-care-services-in-australia\/contents\/expenditure-on-palliative-care\/data-source\u3009 (accessed March 25, 2026)."},{"key":"10.1016\/j.jcpo.2026.100760_bib28","unstructured":"Pharmaceutical Benefits Scheme (PBS). Review of the base discount rate in the PBAC Guidelines. 2022 \u3008https:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2022-07\/Review-of-the-base-discount-rate-in-the-PBAC-Guidelines-July-2022?utm_source=chatgpt.com\u3009."}],"container-title":["Journal of Cancer Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538326000615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538326000615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:08:24Z","timestamp":1794474504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213538326000615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":28,"alternative-id":["S2213538326000615"],"URL":"https:\/\/doi.org\/10.1016\/j.jcpo.2026.100760","relation":{},"ISSN":["2213-5383"],"issn-type":[{"value":"2213-5383","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness and budget impact analysis of pembrolizumab as an adjuvant treatment of resected stage III melanoma from an Australian healthcare system perspective","name":"articletitle","label":"Article Title"},{"value":"Journal of Cancer Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcpo.2026.100760","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100760"}}